Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imatinib dry powder inhalation - Aerovate Therapeutics

Next Previous
Drug Profile

Imatinib dry powder inhalation - Aerovate Therapeutics

Alternative Names: AV-101 - Aerovate Therapeutics

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aerovate Therapeutics
  • Class Amines; Anti-inflammatories; Antineoplastics; Antivirals; Benzamides; Eye disorder therapies; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Bcr-abl tyrosine kinase inhibitors; Discoidin domain receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Pulmonary arterial hypertension

Most Recent Events

  • 14 Nov 2023 Aerovate Therapeutics has patent protection for inhalable Imatinib in the US
  • 30 Jun 2023 Aerovate Therapeutics has patent protection for Imatinib dry powder inhalation in US
  • 22 May 2023 Pharmacokinetics data from a preclinical study in Pulmonary arterial hypertension presented at the American Thoracic Society International Conference (ATS-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top